Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.42M Sell
58,025
-2,064
-3% -$37.3K ﹤0.01% 7286
2026
Q1
$1.05M Buy
60,089
+7,650
+15% +$147K ﹤0.01% 7763
2025
Q4
$694K Buy
52,439
+42,327
+419% +$375K ﹤0.01% 8044
2025
Q3
$59.5K Sell
10,112
-33,006
-77% -$155K ﹤0.01% 11805
2025
Q2
$178K Buy
43,118
+16,598
+63% +$66.9K ﹤0.01% 11327
2025
Q1
$99.7K Buy
+26,520
New +$123K ﹤0.01% 11543

Other funds holding BIOA

Jeff Yass's BIOA Position: Q2 2026 in Review

Jeff Yass reduced its BioAge Labs (BIOA) stake by 3.4% in Q2 2026, selling an estimated $37.3K and leaving 58,025 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #7286.

Jeff Yass first reported a position in BIOA in Q1 2025 and has held it in 6 quarters since. 150 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Jeff Yass held 58,025 shares of BioAge Labs worth $1.42M as of Q2 2026.
  • Jeff Yass sold 2,064 BioAge Labs shares in Q2 2026, an estimated $37.3K.
  • BioAge Labs made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7286 holding.
  • Jeff Yass first reported a position in BioAge Labs in Q1 2025 and has held it in 6 quarters since.
  • 150 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.